Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Table of study acronyms

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques: Injection, Inhibition

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Treatment groups in included trials

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques: Injection

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Summary of findings: bevacizumab versus ranibizumab

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Summary of findings: anti‐VEGF treatment versus control

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Forest plot of comparison: 2 Ranibizumab versus control, outcome: 2.1 Gain of 15 or more letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Forest plot of comparison: 2 Ranibizumab versus control, outcome: 2.2 Gain of 15 or more letters visual acuity at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Adverse events up to 1 year: ranibizumab versus control

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Adverse events up to 2 years: ranibizumab versus control

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 1 Gain of 15 or more letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Forest plot of comparison: 4 Bevacizumab versus ranibizumab, outcome: 4.1 Gain of 15 or more letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 2 Gain of 15 or more letters visual acuity at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Forest plot of comparison: 4 Bevacizumab versus ranibizumab, outcome: 4.2 Gain of 15 or more letters visual acuity at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 3 Loss of fewer than 15 letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 4 Loss of fewer than 15 letters visual acuity at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 5 Visual acuity better than 20/200 at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 6 Visual acuity better than 20/200 at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 7 Mean change in visual acuity at 1 year (number of letters).

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 8 Mean change in visual acuity at 2 years (number of letters).

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 9 Reduction in central retinal thickness at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 10 Reduction in central retinal thickness at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 11 No problems in quality of life domain at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 12 No problems in quality of life domain at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Adverse events up to 1 year: bevacizumab versus ranibizumab

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Adverse events up to 2 years: bevacizumab versus ranibizumab

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 13 Loss of fewer than 30 letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Anti‐VEGF treatment versus control

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: Pathogens

Article Title: Anaplasma ovis Prevalence Assessment and Cross Validation Using Multiparametric Screening Approach in Sheep from Central Tunisia

doi: 10.3390/pathogens11111358

Figure Lengend Snippet: Monitoring of Anaplasmataceae spp., Anaplasma spp., and A. ovis in studied lambs and ewes.

Article Snippet: A total of 698 sera samples were tested using the Anaplasma Antibody Test Kit, cELISA v2 (VMRD, Pullman, WA, USA) according to the manufacturer’s instructions.

Techniques: Infection

Journal: Pathogens

Article Title: Anaplasma ovis Prevalence Assessment and Cross Validation Using Multiparametric Screening Approach in Sheep from Central Tunisia

doi: 10.3390/pathogens11111358

Figure Lengend Snippet: Summary of the molecular and serological detection of A. ovis using PCR and cELISA assays in sheep sampled in the center of Tunisia.

Article Snippet: A total of 698 sera samples were tested using the Anaplasma Antibody Test Kit, cELISA v2 (VMRD, Pullman, WA, USA) according to the manufacturer’s instructions.

Techniques:

Journal: Pathogens

Article Title: Anaplasma ovis Prevalence Assessment and Cross Validation Using Multiparametric Screening Approach in Sheep from Central Tunisia

doi: 10.3390/pathogens11111358

Figure Lengend Snippet: Neighbor-joining tree based on the alignment of partial msp4 sequences (719 bp) of Anaplasma ovis . Multiple sequence alignments were generated with DNAMAN program (Version 5.2.2; Lynnon Biosoft, Quebec, Canada). Numbers associated with nodes represent the percentage of 1000 bootstrap iterations supporting the nodes (only percentages greater than 50% were represented). A. ovis sequences obtained in the present study are highlighted in bold. The host or vector, the strain or isolate name, the country of origin and the GenBank accession number are indicated.

Article Snippet: A total of 698 sera samples were tested using the Anaplasma Antibody Test Kit, cELISA v2 (VMRD, Pullman, WA, USA) according to the manufacturer’s instructions.

Techniques: Sequencing, Generated, Plasmid Preparation